文献速递头颈外科

低剂量纳武利尤单抗联合节拍化疗对比紫杉醇卡铂方案治疗复发或转移性头颈癌的真实世界IV期优效性试验与成本效果分析

A Real-World Phase IV Superiority Trial and Cost-Effectiveness Analysis of the Addition of Low-Dose Nivolumab to Triple Metronomic Chemotherapy Compared to the Paclitaxel Carboplatin Regimen in Recurrent or Metastatic Head and Neck Cancer Patients.
PubMed 文献 · Head Neck · 2025-10-17

该真实世界IV期优效性试验纳入154例接受姑息治疗的复发或转移性头颈鳞癌成人患者,比较低剂量纳武利尤单抗联合口服节拍化疗(TMC-I)与紫杉醇卡铂(PC)方案。结果显示TMC-I组中位OS和中位PFS均显著优于PC组,ORR更高,且耐受性和成本效果合理。

要点

  • TMC-I组中位OS为15.13个月,PC组为9.8个月,差异显著(p<0.01)。
  • TMC-I组中位PFS为11.20个月,PC组为7.41个月,差异显著(p<0.01)。
  • TMC-I组ORR为69.23%,PC组为31.57%,两组间ICER为68 947。

核心结论

  • 在复发或转移性头颈鳞癌姑息治疗中,低剂量免疫治疗联合口服节拍化疗较常规化疗方案显著改善生存、耐受性和成本效果。

研究设计与样本

  • 真实世界IV期优效性试验,招募接受姑息治疗的成人复发或转移性头颈鳞癌患者,分配至TMC-I组或PC组。
  • 共纳入154例患者,TMC-I组78例,PC组76例。
  • 主要终点为中位OS、PFS、ORR和ICER,安全性评估为次要终点。

主要发现

  • TMC-I组中位OS为15.13个月(95% CI, 11.05-19.20),PC组为9.8个月(95% CI, 7.50-12.09),p < 0.01。
  • TMC-I组中位PFS为11.20个月(95% CI, 5.43-16.96),PC组为7.41个月(95% CI, 6.73-8.08),p < 0.01。
  • TMC-I组ORR为69.23%,PC组为31.57%。
  • 两组间ICER为68 947。

临床怎么用

  • 对于复发或转移性头颈鳞癌的姑息治疗,可考虑低剂量纳武利尤单抗联合口服节拍化疗作为优于紫杉醇卡铂方案的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data are available regarding the comparison of low-dose immunotherapy when added to oral metronomic chemotherapy with conventional induction chemotherapy regimens in recurrent/metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC). METHODS: This real-world phase IV superiority trial recruited adult patients with R/M HNSCC being treated with palliative intent. Patients were assigned to TMC-I or PC. The primary endpoints were median OS, PFS, ORR, and ICER, and the safety assessment was the secondary endpoint. RESULTS: A total of 154 patients were recruited: 78 in the TMC-I arm and 76 in the PC arm. The median OS was 15.13 months (95% CI, 11.05-19.20) versus 9.8 months (95% CI, 7.50-12.09) (p < 0.01), and the median PFS was 11.20 months (95% CI, 5.43-16.96) versus 7.41 months (95% CI, 6.73-8.08) (p < 0.01) for the TMC-I and PC arms, respectively. The ORR was 69.23% for TMC-I and 31.57% for the PC arm, respectively. The ICER between both arms was 68 947. CONCLUSION: A significant improvement in survival, tolerability, and reasonable cost-effectiveness was observed with low-dose immunotherapy when added to oral metronomic chemotherapy compared to conventional chemotherapy regimens.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Khadela A, Parikh R, Vaghela J, et al. A Real-World Phase IV Superiority Trial and Cost-Effectiveness Analysis of the Addition of Low-Dose Nivolumab to Triple Metronomic Chemotherapy Compared to the Paclitaxel Carboplatin Regimen in Recurrent or Metastatic Head and Neck Cancer Patients. Head Neck. 2025. PMID: 41104574. doi:10.1002/hed.70077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。